The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes
Open accessAbstract
Background: Li–Fraumeni syndrome (LFS) is a rare autosomal dominant cancer predisposition syndrome. Most families fulfilling the classical diagnostic criteria harbour TP53 germline mutations. However, TP53 germline mutations may also occur in less obvious phenotypes. As a result, different criteria are in use to decide which patients qualify for TP53 mutation analysis, including the LFS, Li–Fraumeni-like (LFL) and Chompret criteria. We investigated which criteria for TP53 mutation analysis resulted in the highest mutation detection rate and sensitivity in Dutch families. We describe the tumour spectrum in TP53-positive families and calculated tumour type specific relative risks. Method: A total of 180 Dutch families referred for TP53 mutation analysis were evaluated. Tumour phenotypes were verified by pathology reports or clinical records. Results: A TP53 germline mutation was identified in 24 families. When the Chompret criteria were used 22/24 mutations were detected (sensitivity 92%, mutation detection rate 21%). In LFS and LFL families 18/24 mutations were found (sensitivity 75%). The two mutations detected outside the ‘Chompret group’ were found in a child with rhabdomyosarcoma and a young woman with breast cancer. In the mutation carriers, in addition to the classical LFS tumour types, colon and pancreatic cancer were also found significantly more often than in the general population. Conclusion: We suggest TP53 mutation testing for all families fulfilling the Chompret criteria. In addition, TP53 mutation testing can be considered in the event of childhood sarcoma and breast cancer before 30 years. In addition to the risk for established LFS tumour types, TP53-positive individuals may also have an elevated risk for pancreatic and colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Schouten, J. P. (2002) · Nucleic Acids Research · doi:10.1093/nar/gnf056 · Cited by 2,699
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 557
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
Birch, Hartley, Tricker, Prosser, P., Condie, Kelsey, Harris, Jones, Binchy, Crowther, et al. (1994) · Cancer Research · Cited by 475
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.312 · Cited by 443
GermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 430
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
Birch, J. M., Hartley, A. L., Tricker, K. J., Prosser, J., Condie, A., Kelsey, A. M., Harris, M., Jones, P. H. M., Binchy, A., & Crowther, D. (1994) · PubMed · Cited by 421
Tumors associated with p53 germline mutations: a synopsis of 91 families.
Kleihues, P., Schäuble, B., Hausen, A. Z., Estève, J., & Ohgaki, H. (1997) · Europe PMC (PubMed Central) · Cited by 411
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
2009 Version of the Chompret Criteria for Li Fraumeni Syndrome
Tinat, J., Bougeard, G., Baert-Desurmont, S., Vasseur, S., Martin, C., Bouvignies, E., Caron, O., Bressac-de Paillerets, B., Berthet, P., Dugast, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7967 · Cited by 348
Sensitivity and predictive value of criteria for p53 germline mutation screening
CHOMPRET, A., ABEL, A., STOPPA-LYONNET, D., BRUGIÈRES, L., PAGÈS, S., FEUNTEUN, J., & BONAÏTI-PELLIÉ, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.43 · Cited by 341
Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors
Varley, J. M., McGown, G., Thorncroft, M., James, L. A., Margison, G. P., Forster, G., Evans, D. G. R., Harris, M., Kelsey, A. M., & Birch, J. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302575 · Cited by 266
Inherited p53 gene mutations in breast cancer.
Sidransky, D., Tokino, T., Helzlsouer, K. J., et al. (1992) · PubMed · Cited by 249
p53 mutations in breast cancer.
Coles, C., Condie, A., Chetty, U., Steel, C., Evans, H. J., & Prosser, J. (1992) · PubMed · Cited by 241
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230 · cited 1×
“germline mutation was found in 29% and 35% of French and American families, respectively, who fulfilled the 2001 Chompret criteria.”
BackgroundGermline p53 Mutations in a Cohort with Childhood Sarcoma: Sex Differences in Cancer Risk
Hwang, S.-J., Lozano, G., Amos, C. I., & Strong, L. C. (2003) · The American Journal of Human Genetics · doi:10.1086/374567 · Cited by 229
High frequency of germline p53 mutations in childhood adrenocortical cancer
Wagner, J., Portwine, C., Rabin, K., Leclerc, J.-M., Narod, S. A., & Malkin, D. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.22.1707 · Cited by 227
Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.
Diller, L., Sexsmith, E., Gottlieb, A., Li, F. P., & Malkin, D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117834 · Cited by 220
Achatz, M. I. W., Olivier, M., Calvez, F. L., Martel-Planche, G., Lopes, A., Rossi, B. M., Ashton-Prolla, P., Giugliani, R., Palmero, E. I., Vargas, F. R., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2005.12.039 · Cited by 217
Germline mutations in the TP53 gene.
Eeles, R. A. (1995) · PubMed · Cited by 211
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history
Lalloo, F., Varley, J., Ellis, D., Moran, A., O'Dair, L., Pharoah, P., & Evans, D. G. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12856-5 · Cited by 202
Screening for germ line TP53 mutations in breast cancer patients.
Børresen‐Dale, A., Andersen, T. I., Garber, J. E., Barbier, N., Thorlacius, S., Eyfjord, J. E., Ottestad, L., Smith‐Sørensen, B., Hovig, E. J., & Malkin, D. M. (1992) · PubMed · Cited by 187
Krutilkova, V., Trková, M., Fleitz, J. M., Gregor, V., Novotna, K., Křepelová, A., Sumerauer, D., Kodet, R., Širůčková, S., Plevová, P., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.01.026 · Cited by 97
Beyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations
Gonzalez, K. D., Noltner, K., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Ngyuen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11031 · Cited by 58
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
Ginsburg, O., Akbari, M. R., Aziz, Z., Young, R., Lynch, H. T., Ghadirian, P., Robidoux, A., Hernández, J. E. L., Vásquez, G., Gomes, M. C. B., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9287-z · Cited by 40
Hayes, V. M., Bleeker, W. A., Verlind, E., et al. (1999) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199903000-00002 · Cited by 29
Late-Onset Common Cancers in a Kindred with an Arg213Gln TP53 Germline Mutation
Ruijs, M., Verhoef, S., Wigbout, G., Pruntel, R., Floore, A. N., de Jong, D., Veer, L. V. ‘., & Menko, F. H. (2006) · Familial Cancer · doi:10.1007/s10689-005-4789-9 · Cited by 15
Self-citation
Cited by
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534
Metadata
- Authors
- Ruijs, M. W. G., Verhoef, S., Rookus, M. A., Pruntel, R., van der Hout, A. H., Hogervorst, F. B. L., Kluijt, I., Sijmons, R. H., Aalfs, C. M., Wagner, A., Ausems, M. G. E. M., Hoogerbrugge, N., van Asperen, C. J., Gomez Garcia, E. B., Meijers-Heijboer, H., ten Kate, L. P., Menko, F. H., & van 't Veer, L. J.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2010-06
- Volume
- 47
- Issue
- 6
- Pages
- 421-428
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2098232585
- Cited by
- 305
- References
- 33
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.